BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company reported sales of $747 ...

A single gene in the shorebird species known as ruffs controls the levels of testosterone in males, and this in turn affects ...

Scientists at Brazil's National Center for Research in Energy and Materials (CNPEM) have discovered a biocatalyst called ...

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

It is a unique member of the plastic family as it can be broken down into its constituent units (or monomers) by PETases, which are enzymes that degrade PET. Until now, scientists have discovered ...

The dsm-firmenich activities to be sold under this transaction to Novonesis represented in 2024 approximately €300 million in total annual net sales. Novones ...

SIRIM Berhad (SIRIM) and Ensu Lifesciences Sdn Bhd (ELSB) today signed a technology licensing agreement to produce the Acne and Blemish Control Skin Care Technology, a skincare product derived from ...

The National Center for Research in Energy and Materials has filed a patent application for the enzyme, which is now being ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

A virus originally found in animals, mpox – which causes the disease of the same name – is now circulating in humans. Since ...

Running a multi-product facility requires expertise. And, while technology is important, human expertise remains the most ...